Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study

This research is being conducted to understand if treatment can be tailored for participants with HPV-related oropharynx cancers using both clinical features (stage of the tumor, smoking status) combined with an investigational HPV blood test. The names of the test and treatments involved in this study are: * NavDx® HPV ctDNA testing (HPV blood test) * Radiation therapy * Chemotherapy: Cisplatin, or Carboplatin and Paclitaxel (not all participants receive any or all of these agents)

Trial Details

NCT ID
NCT04900623
Phase
PHASE2
Sponsor
Jonathan Schoenfeld, MD, MPH
Status
RECRUITING
Cancer Type
HPV Positive Head and Neck Cancer
Interventions
  • NavDx HPV ctDNA Testing
  • Radiotherapy
  • Chemotherapy drug
Locations (sample)
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Boston, Massachusetts, United States|42.35843,-71.05977

Key Eligibility Criteria

  • Participants must meet the following eligibility criteria at the time of screening to be eligible to participate in the study:
  • Subject must have histologically or cytologically confirmed, stage I, II, or III (N3 disease excluded), HPV associated oropharyngeal (tongue base o…
  • \-- Patients with HPV-associated disease of unknown primary (cT0) are eligible
  • HPV status should be confirmed on tissue biopsy or cytologic sample by any of the following:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HPV Positive Head and Neck Cancer Trials on Trialify →